Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
I hold a BS in Cell and Molecular Biology and an MSE in Biomedical Engineering from a top public US university. I am currently an MD/PhD candidate at one of the top medical research centers in the USA.
Founder of insidewallstreet.org uncovering select special situation stocks.
California Real Estate Broker
Author of the erotic novel based on a true story " In Search of a Soul Mate"
CEO and President of Gibralter Financial and Real Estate Services from 2001 to 2008.
CEO of All Valley Mortgage 1993-1995
Private investor, Author and trader from 1999 to present.
Holmes Osborne has been principal of Osborne Global Investments since 2004. Holmes holds the Chartered Financial Analyst designation and a degree in finance from Syracuse University. He has been featured three times in the Wall Street Journal and once in Fortune Magazine and Investors' Business Daily. Holmes has written financial columns for Seeking Alpha, the Motley Fool, and theStreet.com. Client assets are held at Charles Schwab. He lives with his wife Jennifer and daughters Adelaide and Emily.
Please note that I do not read comments posted here, nor respond to messages here. I don't have the time. If you want my attention, you must seek it directly at my blog.
Aswath Damodaran is the Kerschner Family Chair Professor of Finance at the Stern School of Business at New York University. He teaches the corporate finance and equity valuation courses in the MBA program. He received his MBA and Ph.D from the University of California at Los Angeles. His research interests lie in valuation, portfolio management and applied corporate finance.
He has written three books on equity valuation (Damodaran on Valuation, Investment Valuation, The Dark Side of Valuation) and two on corporate finance (Corporate Finance: Theory and Practice, Applied Corporate Finance: A User’s Manual). He has co-edited a book on investment management with Peter Bernstein (Investment Management) and has a book on investment philosophies (Investment Philosophies). His newest book on portfolio management is titled Investment Fables and was released in 2004. His latest book is on the relationship between risk and value, and takes a big picture view of how businesses should deal with risk, and was published in 2007.
He was a visiting lecturer at the University of California, Berkeley, from 1984 to 1986, where he received the Earl Cheit Outstanding Teaching Award in 1985. He has been at NYU since 1986, received the Stern School of Business Excellence in Teaching Award (awarded by the graduating class) in 1988, 1991, 1992, 1999, 2001, 2007, 2008 and 2009, and was the youngest winner of the University-wide Distinguished Teaching Award (in 1990). He was profiled in Business Week as one of the top twelve business school professors in the United States in 1994.
Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
Full-time investor. Formerly buy-side credit analyst (2yrs) covering Japanese + Asian companies. Before that, I was a cross asset derivatives salesperson at a large bulge-bracket firm, based in Tokyo (4yrs). I use Seeking Alpha to clarify and synthesize my investment thought process and to elicit feedback on my theses; additionally I like to connect with other investors and swap ideas.
You can read my finance-related blog at rapercapital.com (less organized than Seeking Alpha writeups, more my random musings on various finance-related topics).
Going forward I will try to tweet my investment-related thoughts/updates to articles/etc. You can follow me on Twitter, my handle is @puppyeh1
Always looking for new ideas across the board. Happy to exchange ideas/share thoughts/swap notes, feel free to private message me. I currently live in Singapore.
B.A. in economics and MBA from top 10 business school. I have over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange (www.newyorkshockexchange.com), a youth mentorship program that teaches investment management skills and competitive basketball skills.
I am a long term value investor, but I am also interested in growth stocks when it is not overpriced.
I enjoy the process of finding out stocks with value, much like a gold-mining experience. Along the way, I also gained a lot of insight on various businesses.
Most of the time, I post articles and comments on Seeking Alpha to get opinions from other people, since it is important to get criticized and avoid the confirmatory bias. I also believe that small investors need to work together to share their research efforts in order to achieve an edge on information.
While I am passionate about investment, I am also passionate about many other things as well, such as Math, Machine Learning, Psychology and Philosophy. I believe life is about having fun, and a big part of that "fun" comes from constant learning and personal improvement.
HORAN Capital Advisors (http://www.horancapitaladvisors.com) is an SEC registered investment advisor that manages investment portfolios for individuals and institutions. Our firm utilizes a disciplined investing approach that should create wealth for our clients over time. Our investment bias is to invest in companies that generate a steady return over time, i.e., singles and doubles. This singles and doubles approach tends to lead to investments in higher quality dividend growth/cash flow growth companies. On the other hand, there are times when a company's stock price seems to be trading below its fair valuation. Short term gains are possible in these situations. I have been managing investment portfolios for individuals and institutions for over fifteen years and believe investing is like running a marathon and not a sprint. Taking the road less traveled, more often than not, leads to higher returns. Visit: The Blog of HORAN Capital Advisors at (http://disciplinedinvesting.blogspot.com/)
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Richard Zeits is an Oil & Gas industry analyst and consultant. His background includes fourteen years as Energy industry-focused investment banker, portfolio manager and senior investment analyst with bulge bracket firms in New York. Zeits Energy Analytics use elaborate proprietary analytics and data bases to provide in-depth industry research, market intelligence, and forecasting.
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
If you got burned in the past at junior mining investments by overly positive newsletter writers, sell side analysts or other (paid) sources which more often than not avoid to mention (hidden) risks or critical flaws, The Critical Investor goes a few steps further, and might provide a fresh, more in-depth, unbiased and critical vision on things, hence the name. For examples of those risks or flaws just think of management overpromising and underdelivering, inactivity, shortfalls in cash, windowdressing, bad trackrecords, negative trends on AISC/cash flows/production grades, depleting reserves without renewal, tricky accounting, bad financing terms, permitting issues, commodity issues like possible equilibrium shifts, too much supply coming online, location issues (climate, local opposition, politics), infrastructure, currency effects, influence of investment groups behind the scenes, project economics not up to standards, companies being overvalued based on important but avoided metrics, etcetcetc.
Being an insider of the sector, talking frequently to industry participants (company management, analysts, fund managers, investment bankers, etc), provides for up to standard insights and useful feedback. By analyzing lots of technical reports, analyst reports, economic studies, interviews, articles and other sources, The Critical Investor has developed extensive knowledge about deposits and projects, which often proves to be useful for identifying threats or opportunities.
Avid and critical mining and mining related stock investor from Europe. Number cruncher, looking for high quality companies, mostly growth/turnaround/catalyst-driven to avoid too much dependence/influence of long term commodity pricing/market sentiments, and often additional long term deep value. About the new Subscriber service: I do write freely available analysis on a few portfolio stockpicks, but most of them are only accessible to subscribers.
Open to research assignments, individual portfolio advise, all related to mining.
Disclaimer: I am no certified financial advisor so always do your own due diligence on possible investments.
I have been a successful Private Investor in the market for the last 17 years. My focus has mostly been on the Tech/Internet sector since I started, but 12 years ago I also got extremely interested in the Gold and Silver sector.
I believe in buying value, and not chasing the next hot stock. I use several basic investing principles, the main one being buying the balance sheet. I wait for opportunities to present themselves and then buy in. I believe in doing your research, and I have a very research intensive focus.
EXP is a graduate from The University of Wall Street and serves as the CEO / Chief Stock Strategist at EXPstocktrader.com research firm.
With over 30 years of trading the market, EXP is an experienced investor using a fundamental and technical approach as a market analyst, chartist, visual analyst, as well as, a trader, author, coach, and serial entrepreneur. Extremely dedicated by investing countless hours investigating, analyzing, then writing about unique stock opportunities, as well as, coaching existing followers worldwide. EXP delivers "Real Facts" to Seeking Alpha and Twitter followers on monthly stock selections. Not all of the research found in the EXPstocktrader Monthly Newsletter is openly published online so EXP's members get updates first. Note: Most stocks covered have a unique niche or value proposition.
The Goal is to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. From the EXPstocktrader.com website you will find an offering for a newsletter that gives interested followers several trading ideas and stock lessons on a monthly basis. SA followers only see a very small part of EXP's published research.
This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them.
EXP resides in the USA, and is thankful to followers worldwide.
You can also follow EXPstocktrader on:
Twitter --- @EXPstocktrader
Website --- http://www.EXPstocktrader.com
Email --- firstname.lastname@example.org
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader.com and SA are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Rick Husband has 30 years experience in buying and selling natural gas, oil, NGL feedstocks and other commodities for exploration & production companies, mid-stream entities and refineries. He has also participated on the hedge committees for several of those companies, and holds a BSBA from the University of Denver in economics. He is a Roving Neihoffian Econometrician.
Engineer by trade and passion. Have worked internationally for over three decades, running my own business. I hold a PhD in engineering, but honestly believe that the school of hard knocks has taught me lessons that are more applicable to my writing here on Seeking Alpha.
My investing interests mostly concern the resource sector, with a focus on precious metals, base metals and energy stocks of all sizes. My research explicitly includes small- and micro-cap juniors, and I try to manage the associated risks in a methodical manner.
Biotech stock trading and investing for 25 years. PhD in biology, MS in computer science.
Extensive experiences in biotech/pharmaceutical companies, in both USA and China, serving middle to senior executive positions. After 12 years of research at top institutions/universities and 10 years of management in biotech/pharmaceutical industry, I am now a full time biotech investor/trader, residing at Las Vegas.
I mainly rely on fundamental analysis to pick biotech stocks, either long or short. I also use proprietary programs to aid my screening process. Currently, I am working with a group of advanced option traders in a quest to tame volatile biotech stocks.
Background: Former securities analyst and brokerage firm owner and
Currently doing investment strategy consulting for institutional investors
Undergraduate degree from Northwestern, Economics
Taught Advanced Financial Markets Class at a University in Chicago
In to Yoga.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
Acting Man has been named after the title of the first chapter of Ludwig von Mises' book "Human Action" - the best treatise on economics ever written. The blog's main author is Pater Tenebrarum, an independent analyst who has been involved with financial markets for 34 years and is writing economic and market analyses for independent research organizations and a European hedge fund consultancy. Acting Man presents articles on the markets and the economy, a mixture of commentary on current events as well as economic theory and history, mainly from an Austrian School of Economics viewpoint. As more authors have joined the site, we have begun to broaden our palette a bit, but our orientation remains the same: pro-free market, anti-state, pro peace.
I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com